免疫保护性硕大利什曼原虫合成T细胞表位
Immunoprotective Leishmania major synthetic T cell epitopes.
作者信息
Jardim A, Alexander J, Teh H S, Ou D, Olafson R W
机构信息
Department of Biochemistry and Microbiology, University of Victoria, BC, Canada.
出版信息
J Exp Med. 1990 Aug 1;172(2):645-8. doi: 10.1084/jem.172.2.645.
Abstract
Using the predictive algorithm of Rothbard and Taylor (1988. EMBO J. 7:93) and the primary structure of gp63 (Button, L., and M.R. McMaster. 1988. J. Exp. Med. 167:724; Miller, R.A., S.G. Reed, and M. Parsons. 1990. Mol. Biochem. Parasitol. 39:267) we have been able to delineate the structures of a number of gp63 T-cell epitopes which stimulate the proliferation of CD4+ cells. One of these synthetic antigens, inoculated subcutaneously with adjuvant, was shown to specifically induce proliferation of the Th1 subset and provided immunoprotection against two species of Leishmania parasites.
摘要
利用罗斯巴德和泰勒（1988年，《欧洲分子生物学组织杂志》第7卷：93页）的预测算法以及gp63的一级结构（巴顿，L.，和M.R.麦克马斯特。1988年，《实验医学杂志》第167卷：724页；米勒，R.A.，S.G.里德，和M.帕森斯。1990年，《分子生物化学寄生虫学》第39卷：267页），我们已经能够描绘出一些刺激CD4 +细胞增殖的gp63 T细胞表位的结构。其中一种合成抗原，与佐剂一起皮下接种，被证明能特异性诱导Th1亚群的增殖，并提供针对两种利什曼原虫寄生虫的免疫保护。
相似文献
1
Immunoprotective Leishmania major synthetic T cell epitopes.免疫保护性硕大利什曼原虫合成T细胞表位
J Exp Med. 1990 Aug 1;172(2):645-8. doi: 10.1084/jem.172.2.645.
2
3
4
T-cell responses and immunity to experimental infection with leishmania major.
Annu Rev Immunol. 1989;7:561-78. doi: 10.1146/annurev.iy.07.040189.003021.
5
Parasite antigens recognized by patients with cutaneous leishmaniasis.皮肤利什曼病患者所识别的寄生虫抗原。
Clin Exp Immunol. 1990 Apr;80(1):77-82. doi: 10.1111/j.1365-2249.1990.tb06444.x.
6
Helper T cells without CD4: control of leishmaniasis in CD4-deficient mice.缺乏CD4的辅助性T细胞：CD4缺陷小鼠中利什曼病的控制
Science. 1993 Sep 10;261(5127):1448-51. doi: 10.1126/science.8367726.
7
Synergy between activated Leishmania major-specific CD4+ T lymphocytes and bone-marrow-derived cells in the exacerbation of murine cutaneous leishmaniasis.活化的利什曼原虫主要特异性CD4 + T淋巴细胞与骨髓来源细胞之间的协同作用在小鼠皮肤利什曼病恶化中的作用
Res Immunol. 1990 Nov-Dec;141(9):865-78. doi: 10.1016/0923-2494(90)90186-3.
8
Immunization of susceptible hosts with a soluble antigen fraction from Leishmania major leads to aggravation of murine leishmaniasis mediated by CD4+ T cells.用来自硕大利什曼原虫的可溶性抗原组分对易感宿主进行免疫会导致由CD4 + T细胞介导的小鼠利什曼病加重。
Eur J Immunol. 1990 Dec;20(12):2533-40. doi: 10.1002/eji.1830201202.
9
Antigen recognition by effector T cells in antileishmanial defense.
J Infect Dis. 1985 Nov;152(5):1057-63. doi: 10.1093/infdis/152.5.1057.
引用本文的文献
1
Vaccination in Leishmaniasis: A Review Article.《利什曼病疫苗接种：综述文章》。
Iran Biomed J. 2022 Jan 1;26(1):1-35. doi: 10.52547/ibj.26.1.35.
2
Peptide Vaccines for Leishmaniasis.利什曼病的肽疫苗。
Front Immunol. 2018 May 11;9:1043. doi: 10.3389/fimmu.2018.01043. eCollection 2018.
3
Visceral Leishmaniasis: Advancements in Vaccine Development via Classical and Molecular Approaches.内脏利什曼病：通过经典和分子方法在疫苗开发方面的进展。
Front Immunol. 2014 Aug 22;5:380. doi: 10.3389/fimmu.2014.00380. eCollection 2014.
4
Experimental models in vaccine research: malaria and leishmaniasis.疫苗研究中的实验模型：疟疾和利什曼病
Braz J Med Biol Res. 2013 Feb;46(2):109-16. doi: 10.1590/1414-431x20122460. Epub 2013 Feb 1.
5
The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.刚地弓形虫肽 AS15 能诱导产生可控制寄生虫负荷的 CD4 T 细胞。
Infect Immun. 2012 Sep;80(9):3279-88. doi: 10.1128/IAI.00425-12. Epub 2012 Jul 9.
6
Vaccine Development Against Leishmania donovani.抗杜氏利什曼原虫疫苗的研制。
Front Immunol. 2012 May 15;3:99. doi: 10.3389/fimmu.2012.00099. eCollection 2012.
7
Characterization of an I-E-restricted, gp63-specific, CD4-T-cell clone from Leishmania major-resistant C3H mice that secretes type 2 cytokines and exacerbates infection with L. major.从对硕大利什曼原虫有抗性的C3H小鼠中分离出的一个I-E限制性、gp63特异性、分泌2型细胞因子并加剧硕大利什曼原虫感染的CD4 T细胞克隆的特性分析。
Infect Immun. 2004 Aug;72(8):4486-93. doi: 10.1128/IAI.72.8.4486-4493.2004.
8
Intradermal infection model for pathogenesis and vaccine studies of murine visceral leishmaniasis.用于小鼠内脏利什曼病发病机制和疫苗研究的皮内感染模型
Infect Immun. 2003 Jan;71(1):401-10. doi: 10.1128/IAI.71.1.401-410.2003.
9
Characterization of Leishmania donovani antigens encapsulated in liposomes that induce protective immunity in BALB/c mice.利什曼原虫杜氏亚种抗原包裹于脂质体中的特性研究，该脂质体可在BALB/c小鼠中诱导保护性免疫。
Infect Immun. 2002 Dec;70(12):6697-706. doi: 10.1128/IAI.70.12.6697-6706.2002.
10
Immunization with a polyprotein vaccine consisting of the T-Cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and Leishmania elongation initiation factor protects against leishmaniasis.用由T细胞抗原硫醇特异性抗氧化剂、硕大利什曼原虫应激诱导蛋白1和利什曼原虫延伸起始因子组成的多蛋白疫苗进行免疫接种可预防利什曼病。
Infect Immun. 2002 Aug;70(8):4215-25. doi: 10.1128/IAI.70.8.4215-4225.2002.
本文引用的文献
1
2
Molecular cloning of the major surface antigen of leishmania.利什曼原虫主要表面抗原的分子克隆
J Exp Med. 1988 Feb 1;167(2):724-9. doi: 10.1084/jem.167.2.724.
3
Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes.用重组到脂质体中的特定膜抗原对皮肤利什曼病进行有效免疫。
J Immunol. 1988 Feb 15;140(4):1274-9.
4
5
6
Characterization of the promastigote surface protease of Leishmania as a membrane-bound zinc endopeptidase.
Mol Biochem Parasitol. 1989 Dec;37(2):235-45. doi: 10.1016/0166-6851(89)90155-2.
7
Leishmania gp63 molecule implicated in cellular adhesion lacks an Arg-Gly-Asp sequence.
Mol Biochem Parasitol. 1990 Mar;39(2):267-74. doi: 10.1016/0166-6851(90)90065-t.
Zotero 插件